Shots:
PharmaShots' designation report provides a concise overview of the latest drug designations by major regulatory authorities, including the FDA, EMA, MHLW and NMPA
The December 2024 report covers designations granted to 43 drugs and 3 devices, encompassing 13 small molecules, 10 biologics, 7 cell and gene therapies & 3 medical devices among others
Significant…
Shots:
The January Edition features RA Capital Management, a global multi-stage investment firm dedicated to healthcare and life sciences
In 2024, RA Capital added 74 companies to its portfolio, investing approximately $8.5B across seven funding rounds, including private and common funding
Welcome to the 2025 series of Know Your Investor, a meticulously crafted report highlighting…
Shots:
In this second installment of Dealmaker 2024, PharmaShots presents an insightful guide to the top M&A deals ranked by deal value
This report highlights Novo Nordisk’s remarkable achievements, including 24 collaborations spanning acquisitions, company formations, contract services, development and commercialization agreements, facility purchases, licensing options, and platform/product purchases. Collectively, these deals amount to…
Shots:
In this second installment of Dealmaker 2024, PharmaShots presents an insightful guide to the top M&A deals ranked by deal value
This report highlights Novo Nordisk’s remarkable achievements, including 24 collaborations spanning acquisitions, company formations, contract services, development and commercialization agreements, facility purchases, licensing options, and platform/product purchases. Collectively, these deals amount to a…
Shots:
The first dose of the J.P. Morgan Special: Dealmaker of the Year report based on the total number of deals signed in 2024
Last year, Roche inked 38 deals comprising acquisitions, contract services, development & commercialization, facility purchase, R&D, platform/product purchases, and sales/co-promotion
Leveraging DealForma’s invaluable insights, PharmaShots brings an on-demand report…
Shots:
The first dose of the J.P. Morgan Special: Dealmaker of the Year report based on the total number of deals signed in 2024
Last year, Roche inked 38 deals comprising acquisitions, contract services, development & commercialization, facility purchase, R&D, platform/product purchases, and sales/co-promotion
Leveraging DealForma’s invaluable insights, PharmaShots brings an on-demand report on the Dealmaker…
Shots:
The WHO’s One Health policy is driving innovation in animal health, emphasizing the intersection of human, animal, and environmental care
The global animal health market, valued at $62.4B in 2023, is expected to grow at a CAGR of 9%, reaching $114B by 2030
PharmaShots presents a comprehensive report on the Top 20 Animal Health Companies of…
Shots:
A longstanding equities business within Citadel, Surveyor Capital invests in the consumer, financials, healthcare, industrials, and Technology, Media & Telecom sectors
In 2023, Surveyor participated in four funding rounds, investing approximately $2.35B and adding 17 companies to its portfolio
For a curated report on a specific investor or venture capital firm, reach out to…
Shots:
Cell and gene therapies provide a promising opportunity to enhance care for unmet healthcare needs. Biopharma companies are actively exploring these therapies across multiple indications to address healthcare gaps in rare and chronic diseases
In 2023, the cell and gene therapy market was valued at $18.2B and is projected to grow to $117.46B by…
Shots:
CDMOs are at the forefront of pharmaceutical manufacturing, shaping the industry's growth by meeting the increasing global demand for pharmaceutical products
In 2023, the global CDMO market was valued at $224.86B, with projections to reach $465.14B by 2032, demonstrating a CAGR of 8.5%
PharmaShots presents a comprehensive report on the 20 Contract Development and…

